[Nivolumab for the treatment of advanced melanoma]
González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A
Record ID 32017000308
Spanish
Authors' recommendations:
High quality evidence showed that the use of nivolumab as first-line therapy, in patients with advanced (metastatic or irresecable) melanoma without BRAF mutations would increase the rate of one year progression-free and overall survival when compared with dacarbazine. In this setting, its use in combination with ipilimumab would increase progression-free survival and the incidence of severe adverse effects, although the results on overall survival are not available yet. In patients who progressed after ipilimumab or BRAF inhibitors, its use as monotherapy would increase progression-free survival with a lower incidence of adverse effects when compared with the use of chemotherapy. No comparative studies versus other options currently considered first or second-line therapy (pembrolizumab or BRAF/MEK inhibitors) have been found.
There is consensus among the clinical practice guidelines to recommend its use as an option in first line and/or second line therapy; being covered in these situations by different public and private health sponsors consulted.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Melanoma
- Immune Checkpoint Inhibitors
- Nivolumab
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.